For example, JAK-STAT pathway inhibitors (e.g., ruxolitinib) have demonstrated efficacy in CRLF2-rearranged Ph-like B-ALL but require combination with other therapeutic approaches due to resistance observed with monotherapy [96]. This evidence concerns the gene CRLF2 and precursor B-cell acute lymphoblastic leukemia.